The AAIC 2026 primary-care study found C2N's PrecivityAD2 blood test helped primary-care doctors diagnose Alzheimer's almost as accurately as dementia specialists. For patients with memory symptoms, that means a usable answer from a regular clinic visit, with uneven insurance coverage and clear follow-up still needed. PrecivityAD2 measures amyloid-beta 42/40 plus p-tau217, blood markers tied to Alzheimer pathology. According to the Alzheimer's Association, Lund University researchers led by Sebastian Palmqvist tested it in 1,310 patients with cognitive symptoms and 165 primary-care and specialist doctors in Sweden, with results presented July 14, 2026, in the AAIC announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How accurate was the test in primary care?
- What changed for patients after results?
- Who can get the test now?
- What will it cost?
- What should you ask at follow-up?
How accurate was the test in primary care?
Primary-care accuracy rose from 65% before blood results to 93% after, nearly matching specialists at 94%, according to Medscape Medical News in its AAIC report. Head-to-head comparison put both groups around 90% with test support. That is a large gain for first-contact care.
The test was most useful for ruling out Alzheimer's. A negative result gives strong confidence that Alzheimer pathology is absent. Doctors can then look harder at other causes like vascular disease, sleep apnea, depression, thyroid problems, or medication effects.
What changed for patients after results?
Doctors changed the diagnosis in about 30% of patients after seeing blood results. They also changed planned management, referrals, workup, or follow-up exams in more than half of cases. Those shifts matter because early direction shapes safety advice and family planning.
A positive result does not by itself set treatment. A borderline result needs careful review, not quick reassurance. Ask whether the result changes your working diagnosis today.
Who can get the test now?
The FDA cleared PrecivityAD2 on Aug. 20, 2026, for adults age 40 and older with signs or symptoms of cognitive impairment undergoing evaluation, according to the Longevity Benchmark summary of the company and agency statements in the FDA clearance summary. It is not cleared as a screening test for people without symptoms.
It is also not a stand-alone diagnosis and must be used with clinical assessment. C2N said the FDA-cleared version would be available later in 2026 while its laboratory-developed version remained orderable. In practice, access runs through a doctor evaluating memory concerns. Primary care is the likely entry point for most patients.
What will it cost?
C2N lists no public price. The company describes financial assistance and payment plans, with coverage varying by payer. That makes the out-of-pocket amount hard to predict from a website.
- Ask the ordering clinic for the billing code and expected patient cost.
- Ask whether your plan needs prior authorization.
- Ask about C2N assistance or a payment plan before the draw.
- Ask whether confirmatory spinal-fluid or amyloid-PET testing would add separate cost.
What should you ask at follow-up?
Use the visit to turn a lab value into a plan. Ask what a positive, borderline, or negative means for you. Ask whether a specialist referral is needed and whether spinal-fluid or amyloid-PET confirmation is required before changing drugs.
The Alzheimer's Association's 2025 blood-biomarker guideline supports this triage approach, where a strong test may rule out pathology but a positive still needs confirmation, as described in the guideline announcement. Also ask how results affect prescriptions, driving and home safety, work duties, and when to return. Bring a family member or care partner to record the next steps.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Is Established and What Remains Uncertain for Primary Care Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Is Established and What Remains Uncertain for Primary Care Patients
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: What Is Established and What Remains Uncertain for Primary Care Patients
